8-K Announcements
6Material company update
May 5, 2026·SEC
Material company update
Apr 24, 2026·SEC
Material company update
Apr 23, 2026·SEC
Cumberland Pharmaceuticals Inc.(CPIX)Earnings, Financials & Key Ratios
CPIX•NASDAQ
$4.37
$65M mkt cap·Price updated May 6, 2026
AboutCumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, rheumatology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It also develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases; and a product candidate that is in Phase II clinical trial for cholesterol reducing agent to use in the hospital setting. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.Show more
- Revenue$45M+17.6%
- EBITDA$2M+740.9%
- Net Income-$3M+56.2%
- EPS (Diluted)-0.19+58.7%
- Gross Margin85.02%+2.9%
- EBITDA Margin5.6%+645.2%
- Operating Margin-6.27%+63.1%
- Net Margin-6.37%+62.8%
- ROE-12.05%+51.8%
- ROIC-8.65%+51.1%
- Debt/Equity0.41-54.5%
- Interest Coverage-5.63+41.8%
CPIX Key Insights
Cumberland Pharmaceuticals Inc. (CPIX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
CPIX Price & Volume
Cumberland Pharmaceuticals Inc. (CPIX) stock price & volume — 10-year historical chart
Loading chart...
CPIX Growth Metrics
Cumberland Pharmaceuticals Inc. (CPIX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years2.88%
5 Years3.52%
3 Years1.95%
TTM2.08%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-125.33%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-97.76%
Return on Capital
10 Years-9.21%
5 Years-11.22%
3 Years-11.99%
Last Year-6.64%
CPIX Recent Earnings
Cumberland Pharmaceuticals Inc. (CPIX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 1/12 qtrs (50%)●Beat Revenue 2/12 qtrs (100%)
Q2 2026Latest
May 5, 2026EPS
$0.13
Est $0.13
+0.0%
Revenue
$9M
Est $9M
+7.4%
Q2 2026
Mar 3, 2026EPS
$0.01
Est $0.13
+92.3%
Revenue
$14M
Est $9M
+60.9%
Q4 2025
Nov 4, 2025EPS
$0.06
Revenue
$8M
Q3 2025
Aug 5, 2025EPS
$0.02
Revenue
$11M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $0.13vs $0.13+0.0% | $9Mvs $9M+7.4% |
| Q2 2026 | Mar 3, 2026 | $0.01vs $0.13+92.3% | $14Mvs $9M+60.9% |
| Q4 2025 | Nov 4, 2025 | $0.06 | $8M |
| Q3 2025 | Aug 5, 2025 | $0.02 | $11M |
Based on last 12 quarters of dataView full earnings history →
CPIX Peer Comparison
Cumberland Pharmaceuticals Inc. (CPIX) competitors in Specialty pharma brand consolidators — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 HROW | 1.5B | 40.27 | -287.64 | 36.41% | -1.89% | -10.07% | 4.84 | |
 PRPH | 5.82M | 0.14 | -0.05 | -84.75% | -38.72% | -6.08% | 3.34 | |
 AYTU | 16.08M | 2.56 | -1.19 | 1.84% | -39.02% | -172.12% | 1.21 | |
 CODA | 134.35M | 11.92 | 32.22 | 30.75% | 14.78% | 7.17% | 0.01 | |
 AMRX | 4.28B | 13.62 | 61.91 | 8.05% | 2.39% | 7.47% | 0.13 | |
 LXRX | 677.89M | 1.60 | -11.43 | 60.24% | -101.08% | -41.94% | 0.58 | |
 PCRX | 931.85M | 23.69 | 148.06 | 3.63% | 1.27% | 1.31% | 0.66 | |
 PAHC | 2.38B | 58.64 | 49.28 | 27.37% | 6.29% | 30.81% | 2.67 |
Compare CPIX vs Peers
Cumberland Pharmaceuticals Inc. (CPIX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CPIX Income Statement
Cumberland Pharmaceuticals Inc. (CPIX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 41.15M | 40.74M | 34.39M | 37.44M | 35.99M | 42.01M | 39.55M | 37.87M | 44.52M | 41.94M |
| Revenue Growth % | 24.6% | -0.99% | -15.59% | 8.88% | -3.89% | 16.75% | -5.85% | -4.26% | 17.57% | 2.08% |
| Cost of Goods Sold | 7.37M | 7.38M | 7.42M | 8.65M | 8.81M | 9.12M | 6.07M | 6.59M | 6.67M | 7.18M |
| COGS % of Revenue | 17.91% | 18.11% | 21.58% | 23.11% | 24.49% | 21.71% | 15.34% | 17.39% | 14.98% | - |
| Gross Profit | 33.78M▲ 0% | 33.36M▼ 1.2% | 26.97M▼ 19.2% | 28.79M▲ 6.8% | 27.17M▼ 5.6% | 32.89M▲ 21.0% | 33.49M▲ 1.8% | 31.28M▼ 6.6% | 37.85M▲ 21.0% | 34.76M▲ 0% |
| Gross Margin % | 82.09% | 81.89% | 78.42% | 76.89% | 75.51% | 78.29% | 84.66% | 82.61% | 85.02% | 82.89% |
| Gross Profit Growth % | 24.8% | -1.23% | -19.17% | 6.75% | -5.61% | 21.04% | 1.8% | -6.58% | 21.01% | - |
| Operating Expenses | 37.86M | 40.75M | 36.26M | 35.17M | 34.85M | 38.6M | 43.04M | 37.71M | 40.65M | 41.98M |
| OpEx % of Revenue | 92.01% | 100.03% | 105.43% | 93.93% | 96.85% | 91.87% | 108.82% | 99.59% | 91.3% | - |
| Selling, General & Admin | 31.52M | 30.66M | 25.25M | 24.96M | 24.8M | 26.84M | 29.1M | 28.15M | 31.05M | 31.97M |
| SG&A % of Revenue | 76.61% | 75.26% | 73.43% | 66.67% | 68.9% | 63.89% | 73.58% | 74.34% | 69.73% | - |
| Research & Development | 3.9M | 7.32M | 6.87M | 5.77M | 5.68M | 6.69M | 5.83M | 4.82M | 5.57M | 5.73M |
| R&D % of Revenue | 9.48% | 17.97% | 19.97% | 15.42% | 15.8% | 15.92% | 14.75% | 12.72% | 12.5% | - |
| Other Operating Expenses | 2.44M | 2.77M | 4.13M | 4.43M | 4.37M | 5.07M | 8.1M | 4.75M | 4.03M | 4M |
| Operating Income | -4.08M▲ 0% | -7.39M▼ 81.1% | -9.29M▼ 25.7% | -6.38M▲ 31.3% | -7.68M▼ 20.3% | -5.7M▲ 25.7% | -9.55M▼ 67.5% | -6.43M▲ 32.7% | -2.79M▲ 56.6% | -7.21M▲ 0% |
| Operating Margin % | -9.92% | -18.14% | -27.01% | -17.04% | -21.34% | -13.58% | -24.16% | -16.99% | -6.27% | -17.2% |
| Operating Income Growth % | -184.79% | -81.09% | -25.67% | 31.29% | -20.31% | 25.69% | -67.48% | 32.68% | 56.59% | - |
| EBITDA | -1.43M | -4.41M | -4.88M | -1.63M | -3.07M | -376.82K | -1.45M | -389.11K | 2.49M | -3.53M |
| EBITDA Margin % | -3.48% | -10.82% | -14.2% | -4.36% | -8.53% | -0.9% | -3.67% | -1.03% | 5.6% | -8.42% |
| EBITDA Growth % | -248.75% | -207.48% | -10.8% | 66.56% | -88.06% | 87.73% | -285.34% | 73.2% | 740.93% | -233.03% |
| D&A (Non-Cash Add-back) | 2.65M | 2.98M | 4.4M | 4.75M | 4.61M | 5.33M | 8.1M | 6.04M | 5.29M | 3.68M |
| EBIT | -3.78M | -10.61M | -9.04M | -6.31M | -5.46M | -5M | -5.62M | -5.86M | -2.79M | -3.73M |
| Net Interest Income | 206.42K | 368.64K | -2.82K | -188.28K | -71.95K | -487.59K | -381.01K | -271.06K | -19.24K | 18.85K |
| Interest Income | 299.33K | 564.48K | 243.36K | 75.34K | 26.08K | 98.41K | 286.85K | 334.44K | 476.75K | 429.07K |
| Interest Expense | 92.9K | 195.85K | 246.19K | 263.63K | 98.03K | 586K | 667.86K | 605.51K | 495.99K | 246.35K |
| Other Income/Expense | 206.42K | 368.64K | -2.82K | -188.28K | 2.12M | 123.74K | 3.27M | -33.98K | -32.46K | -2.18K |
| Pretax Income | -3.87M▲ 0% | -7.02M▼ 81.2% | -9.29M▼ 32.3% | -6.57M▲ 29.3% | -5.56M▲ 15.3% | -5.58M▼ 0.3% | -6.28M▼ 12.6% | -6.47M▼ 2.9% | -2.82M▲ 56.3% | -7.22M▲ 0% |
| Pretax Margin % | -9.42% | -17.24% | -27.02% | -17.55% | -15.46% | -13.29% | -15.89% | -17.08% | -6.34% | -17.2% |
| Income Tax | 4.17M | 16.64K | -79.32K | 55.9K | 34.89K | 68.85K | 45.77K | -22.67K | 40.26K | 30.71K |
| Effective Tax Rate % | -107.74% | -0.24% | 0.85% | -0.85% | -0.63% | -1.23% | -0.73% | 0.35% | -1.43% | -0.43% |
| Net Income | -7.98M▲ 0% | -6.96M▲ 12.7% | -3.54M▲ 49.2% | -3.34M▲ 5.6% | -3.51M▼ 5.0% | -5.57M▼ 58.8% | -6.28M▼ 12.7% | -6.48M▼ 3.2% | -2.84M▲ 56.2% | -7.38M▲ 0% |
| Net Margin % | -19.39% | -17.09% | -10.29% | -8.92% | -9.75% | -13.26% | -15.88% | -17.11% | -6.37% | -17.6% |
| Net Income Growth % | -744.58% | 12.73% | 49.19% | 5.61% | -5.04% | -58.81% | -12.73% | -3.19% | 56.23% | -125.33% |
| Net Income (Continuing) | -8.05M | -10.82M | -9.21M | -6.63M | -5.6M | -5.65M | -6.33M | -6.44M | -2.86M | -7.4M |
| Discontinued Operations | 0 | 0 | 5.67M | 3.21M | 1.99M | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | -198.56K | -274.27K | -37.62K | -117.12K | -212.33K | -292.13K | -343.57K | -307.52K | -336.1K | -333.51K |
| EPS (Diluted) | -0.50▲ 0% | -0.45▲ 10.0% | -0.23▲ 48.9% | -0.22▲ 4.3% | -0.24▼ 9.1% | -0.38▼ 58.3% | -0.44▼ 15.8% | -0.46▼ 4.5% | -0.19▲ 58.7% | -0.49▲ 0% |
| EPS Growth % | -759.11% | 10% | 48.89% | 4.35% | -9.09% | -58.33% | -15.79% | -4.55% | 58.7% | -97.76% |
| EPS (Basic) | -0.50 | -0.45 | -0.23 | -0.22 | -0.24 | -0.38 | -0.44 | -0.46 | -0.19 | - |
| Diluted Shares Outstanding | 15.91M | 15.61M | 15.4M | 15.16M | 14.9M | 14.56M | 14.3M | 14.06M | 14.96M | 14.96M |
| Basic Shares Outstanding | 15.91M | 15.57M | 15.4M | 15.16M | 14.9M | 14.56M | 14.3M | 14.06M | 14.96M | 14.96M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
CPIX Balance Sheet
Cumberland Pharmaceuticals Inc. (CPIX) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 68.68M | 74.87M | 50.16M | 49.97M | 45.69M | 45.87M | 35.71M | 36.45M | 37.06M | 32.79M |
| Cash & Short-Term Investments | 50.09M | 36.23M | 28.21M | 24.75M | 27.04M | 19.76M | 18.32M | 17.96M | 11.44M | 11.01M |
| Cash Only | 45.41M | 27.94M | 28.21M | 24.75M | 27.04M | 19.76M | 18.32M | 17.96M | 11.44M | 11.01M |
| Short-Term Investments | 4.67M | 8.29M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 8.4M | 7.84M | 7.86M | 12.38M | 6.88M | 13.16M | 9.76M | 11.7M | 16.94M | 14.26M |
| Days Sales Outstanding | 74.46 | 70.28 | 83.42 | 120.67 | 69.76 | 114.37 | 90.05 | 112.79 | 138.92 | 113.04 |
| Inventory | 6.74M | 27.83M | 8.87M | 10.64M | 8.43M | 9.86M | 4.61M | 4M | 6.23M | 5.45M |
| Days Inventory Outstanding | 333.67 | 1.38K | 436.31 | 448.74 | 349.2 | 394.82 | 277.32 | 221.68 | 340.82 | 226.83 |
| Other Current Assets | 0 | 0 | 2.46M | 0 | 0 | 3.08M | 3.03M | 2.79M | 2.45M | 2.07M |
| Total Non-Current Assets | 24.55M | 37.83M | 54.39M | 46.49M | 38.77M | 47.05M | 46.06M | 39.13M | 39.76M | 38.21M |
| Property, Plant & Equipment | 528.88K | 771.21K | 3.71M | 2.6M | 1.47M | 5.5M | 7.04M | 6.45M | 8.61M | 7.86M |
| Fixed Asset Turnover | 77.81x | 52.83x | 9.27x | 14.39x | 24.53x | 7.63x | 5.62x | 5.87x | 5.17x | 5.28x |
| Goodwill | 0 | 784K | 882K | 882K | 882K | 914K | 914K | 914K | 914K | 914K |
| Intangible Assets | 21.44M | 33.66M | 30.92M | 28.12M | 23.95M | 30.59M | 22.61M | 17.97M | 14.03M | 12.79M |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3.99M | 3.99M |
| Other Non-Current Assets | 2.49M | 2.53M | 18.85M | 14.89M | 12.47M | 10.05M | 15.5M | 13.79M | 12.23M | 53.42M |
| Total Assets | 93.23M▲ 0% | 112.69M▲ 20.9% | 104.55M▼ 7.2% | 96.46M▼ 7.7% | 84.46M▼ 12.4% | 92.93M▲ 10.0% | 81.78M▼ 12.0% | 75.58M▼ 7.6% | 76.82M▲ 1.6% | 71M▲ 0% |
| Asset Turnover | 0.44x | 0.36x | 0.33x | 0.39x | 0.43x | 0.45x | 0.48x | 0.50x | 0.58x | 0.60x |
| Asset Growth % | -0.18% | 20.87% | -7.23% | -7.73% | -12.44% | 10.02% | -12% | -7.57% | 1.64% | -24.5% |
| Total Current Liabilities | 17.69M | 27.8M | 24.15M | 25.67M | 19.28M | 28.58M | 27.98M | 31.62M | 36.74M | 34.49M |
| Accounts Payable | 8.98M | 11.09M | 9.99M | 13.4M | 9.64M | 10.82M | 14.04M | 13.91M | 18.57M | 16.54M |
| Days Payables Outstanding | 444.7 | 548.79 | 491.51 | 565.08 | 399.37 | 433.07 | 844.58 | 771.14 | 1.02K | 793.34 |
| Short-Term Debt | 0 | 0 | 0 | 2.19M | 0 | 0 | 0 | 5.1M | 467.77K | 485.16K |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 6.33M | 15.45M | 9.03M | 5.99M | 5.96M | 13.57M | 10.79M | 10.18M | 17.71M | 17.47M |
| Current Ratio | 3.88x | 2.69x | 2.08x | 1.95x | 2.37x | 1.60x | 1.28x | 1.15x | 1.01x | 1.01x |
| Quick Ratio | 3.50x | 1.69x | 1.71x | 1.53x | 1.93x | 1.26x | 1.11x | 1.03x | 0.84x | 0.84x |
| Cash Conversion Cycle | -36.57 | 898.12 | 28.22 | 4.32 | 19.59 | 76.12 | -477.2 | -436.67 | -536.75 | -453.47 |
| Total Non-Current Liabilities | 11.62M | 29.32M | 29.31M | 23.92M | 22.58M | 28.37M | 24.53M | 21.42M | 15.53M | 15.2M |
| Long-Term Debt | 9.8M | 20M | 18.5M | 15M | 15M | 16.2M | 12.78M | 10.18M | 5.24M | 9.58M |
| Capital Lease Obligations | 0 | 0 | 2.08M | 1.06M | 90.02K | 4.59M | 5.3M | 4.94M | 4.47M | 13.78M |
| Deferred Tax Liabilities | 2.07M | 1.97M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 1.82M | 9.32M | 8.74M | 7.86M | 7.49M | 7.59M | 6.45M | 6.3M | 5.82M | 23.69M |
| Total Liabilities | 29.31M | 57.12M | 53.46M | 49.59M | 41.86M | 56.95M | 52.52M | 53.04M | 52.28M | 49.69M |
| Total Debt | 9.8M | 20M | 21.5M | 19.26M | 16.06M | 20.96M | 18.43M | 20.57M | 10.18M | 10.07M |
| Net Debt | -35.61M | -7.94M | -6.72M | -5.49M | -10.98M | 1.2M | 106.86K | 2.61M | -1.26M | -937.46K |
| Debt / Equity | 0.15x | 0.36x | 0.42x | 0.41x | 0.38x | 0.58x | 0.63x | 0.91x | 0.41x | 0.41x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | 4.08x | -2.85x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | -0.51x | -0.51x |
| Interest Coverage | -40.71x | -54.17x | -36.74x | -23.92x | -55.74x | -8.52x | -8.41x | -9.68x | -5.63x | -15.15x |
| Total Equity | 63.92M▲ 0% | 55.57M▼ 13.1% | 51.09M▼ 8.1% | 46.87M▼ 8.2% | 42.6M▼ 9.1% | 35.97M▼ 15.6% | 29.26M▼ 18.7% | 22.55M▼ 22.9% | 24.54M▲ 8.9% | 21.3M▲ 0% |
| Equity Growth % | -12.58% | -13.06% | -8.07% | -8.24% | -9.11% | -15.56% | -18.66% | -22.95% | 8.86% | -4.2% |
| Book Value per Share | 4.02 | 3.56 | 3.32 | 3.09 | 2.86 | 2.47 | 2.05 | 1.60 | 1.64 | 1.42 |
| Total Shareholders' Equity | 64.12M | 55.84M | 51.12M | 46.99M | 42.81M | 36.27M | 29.6M | 22.85M | 24.88M | 21.64M |
| Common Stock | 52.41M | 51.1M | 49.91M | 49.12M | 48.45M | 47.47M | 47.09M | 46.82M | 51.68M | 51.73M |
| Retained Earnings | 11.71M | 4.75M | 1.21M | -2.13M | -5.64M | -11.21M | -17.49M | -23.97M | -26.8M | -30.09M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | -198.56K | -274.27K | -37.62K | -117.12K | -212.33K | -292.13K | -343.57K | -307.52K | -336.1K | -333.51K |
CPIX Cash Flow Statement
Cumberland Pharmaceuticals Inc. (CPIX) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -557.71K | 3.11M | 3.06M | 5.42M | 6.34M | 8.45M | 6.09M | -612.19K | 4.93M | 4.93M |
| Operating CF Margin % | -1.36% | 7.64% | 8.89% | 14.46% | 17.63% | 20.12% | 15.41% | -1.62% | 11.08% | - |
| Operating CF Growth % | -197.93% | 658.12% | -1.81% | 77.17% | 17.13% | 33.28% | -27.91% | -110.05% | 905.72% | -51.94% |
| Net Income | -8.05M | -7.04M | -3.54M | -3.42M | -3.6M | -5.65M | -6.28M | -6.48M | -2.84M | -7.38M |
| Depreciation & Amortization | 2.65M | 2.98M | 4.4M | 4.75M | 4.61M | 5.33M | 5.77M | 6.04M | 5.29M | 5.25M |
| Stock-Based Compensation | 1.49M | 1.36M | 1.49M | 1.05M | 741.87K | 447.5K | 365.04K | 301.89K | 0 | 359.69K |
| Deferred Taxes | 4.21M | 81.89K | 0 | 21.8K | -192.82K | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -65.21K | -150.44K | 2.34M | -515.72K | -3.39M | -2.64M | 1.6M | -1.77M | 319.78K | 759.11K |
| Working Capital Changes | -784.76K | 5.87M | -1.64M | 3.53M | 8.18M | 10.97M | 4.63M | 1.29M | 2.16M | 2.45M |
| Change in Receivables | -1.06M | 550.86K | -1.4M | -4.52M | 5.5M | -6.12M | 3.4M | -1.94M | -5.24M | -3.77M |
| Change in Inventory | -1.37M | 460.5K | 1.11M | 2.13M | 4.82M | 1.38M | -23.14K | 2.41M | 2.24M | 1.98M |
| Change in Payables | 2.31M | 4.31M | 0 | 6.57M | -757.59K | 15.07M | 3.72M | -991.36K | 6.71M | 7.38M |
| Cash from Investing | 9.51M | -27.72M | 2.3M | -1.76M | -501.89K | -13.67M | -105.69K | 57.84K | -4.71M | -3.54M |
| Capital Expenditures | -1.49M | -4.28M | -246.2K | -2.11M | -354.46K | -2.07M | -453.05K | -179.71K | -182.31K | -58.72K |
| CapEx % of Revenue | 3.62% | 10.49% | 0.72% | 5.65% | 0.98% | 4.94% | 1.15% | 0.47% | 0.41% | - |
| Acquisitions | 1.21M | -20M | -5M | 0 | 0 | -13.5M | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -1.21M | -7.27M | 7.54M | 356.14K | 52.57K | 1.9M | 347.36K | 237.56K | -47K | 160.34K |
| Cash from Financing | 1.95M | 7.14M | -5.08M | -7.12M | -3.55M | -2.06M | -7.42M | 196.9K | -6.75M | -1.98M |
| Debt Issued (Net) | 5.7M | 10.2M | -1.5M | -3.5M | 0 | 1.2M | -3.42M | 2.49M | -10.04M | 0 |
| Equity Issued (Net) | -3.72M | -2.68M | -3.49M | -1.85M | -1.39M | -1.05M | -740.53K | -579.05K | -263.48K | -17.61K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | -3.72M | -2.88M | -3.49M | -1.85M | -1.39M | -1.05M | -740.53K | -579.05K | -263.48K | -78.61K |
| Other Financing | -27.95K | -383.31K | -85.61K | -1.76M | -2.17M | -2.21M | -3.27M | -1.72M | 3.55M | -1.97M |
| Net Change in Cash | 10.9M▲ 0% | -17.47M▼ 260.3% | 273.68K▲ 101.6% | -3.46M▼ 1363.8% | 2.29M▲ 166.1% | -7.28M▼ 418.4% | -1.44M▲ 80.3% | -357.44K▲ 75.1% | -6.52M▼ 1723.9% | -4.1M▲ 0% |
| Free Cash Flow | -2.05M▲ 0% | -1.16M▲ 43.2% | 2.81M▲ 341.8% | 3.3M▲ 17.5% | 5.99M▲ 81.4% | 6.38M▲ 6.5% | 5.64M▼ 11.6% | -791.9K▼ 114.0% | 4.83M▲ 710.5% | 1.33M▲ 0% |
| FCF Margin % | -4.97% | -2.85% | 8.17% | 8.82% | 16.64% | 15.19% | 14.26% | -2.09% | 10.86% | 3.16% |
| FCF Growth % | -31.07% | 43.21% | 341.77% | 17.47% | 81.39% | 6.54% | -11.58% | -114.04% | 710.51% | -75.16% |
| FCF per Share | -0.13 | -0.07 | 0.18 | 0.22 | 0.40 | 0.44 | 0.39 | -0.06 | 0.32 | 0.32 |
| FCF Conversion (FCF/Net Income) | 0.07x | -0.45x | -0.86x | -1.62x | -1.81x | -1.52x | -0.97x | 0.09x | -1.74x | -0.18x |
| Interest Paid | 14.99K | 95.97K | 0 | 0 | 0 | 523.16K | 647.14K | 0 | 0 | 0 |
| Taxes Paid | 18K | 15.44K | 0 | 0 | 0 | 3.3K | 108.82K | 15K | 0 | 0 |
CPIX Key Ratios
Cumberland Pharmaceuticals Inc. (CPIX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -11.64% | -11.65% | -6.63% | -6.82% | -7.84% | -14.18% | -19.25% | -25.02% | -12.05% | -29.73% |
| Return on Invested Capital (ROIC) | -8.62% | -14.6% | -15.14% | -11.16% | -15.77% | -12.44% | -21.54% | -17.7% | -8.65% | -8.65% |
| Gross Margin | 82.09% | 81.89% | 78.42% | 76.89% | 75.51% | 78.29% | 84.66% | 82.61% | 85.02% | 82.89% |
| Net Margin | -19.39% | -17.09% | -10.29% | -8.92% | -9.75% | -13.26% | -15.88% | -17.11% | -6.37% | -17.6% |
| Debt / Equity | 0.15x | 0.36x | 0.42x | 0.41x | 0.38x | 0.58x | 0.63x | 0.91x | 0.41x | 0.41x |
| Interest Coverage | -40.71x | -54.17x | -36.74x | -23.92x | -55.74x | -8.52x | -8.41x | -9.68x | -5.63x | -15.15x |
| FCF Conversion | 0.07x | -0.45x | -0.86x | -1.62x | -1.81x | -1.52x | -0.97x | 0.09x | -1.74x | -0.18x |
| Revenue Growth | 24.6% | -0.99% | -15.59% | 8.88% | -3.89% | 16.75% | -5.85% | -4.26% | 17.57% | 2.08% |
CPIX SEC Filings & Documents
Cumberland Pharmaceuticals Inc. (CPIX) SEC filings — annual & quarterly reports (10-K, 10-Q)
CPIX Frequently Asked Questions
Cumberland Pharmaceuticals Inc. (CPIX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Cumberland Pharmaceuticals Inc. (CPIX) reported $41.9M in revenue for fiscal year 2025. This represents a 292% increase from $10.7M in 2005.
Cumberland Pharmaceuticals Inc. (CPIX) grew revenue by 17.6% over the past year. This is strong growth.
Cumberland Pharmaceuticals Inc. (CPIX) reported a net loss of $7.4M for fiscal year 2025.
Dividend & Returns
Cumberland Pharmaceuticals Inc. (CPIX) has a return on equity (ROE) of -12.0%. Negative ROE indicates the company is unprofitable.
Cumberland Pharmaceuticals Inc. (CPIX) generated $1.3M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
Explore More CPIX
Cumberland Pharmaceuticals Inc. (CPIX) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates